Market Research Logo

Hypercholesterolemia - Pipeline Review, H1 2018

Hypercholesterolemia - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H1 2018, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 9, 13, 4, 1, 17, 5 and 3 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 6 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Hypercholesterolemia - Overview
Hypercholesterolemia - Therapeutics Development
Hypercholesterolemia - Therapeutics Assessment
Hypercholesterolemia - Companies Involved in Therapeutics Development
Hypercholesterolemia - Drug Profiles
Hypercholesterolemia - Dormant Projects
Hypercholesterolemia - Discontinued Products
Hypercholesterolemia - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Hypercholesterolemia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hypercholesterolemia - Pipeline by AFFiRiS AG, H1 2018
Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H1 2018
Hypercholesterolemia - Pipeline by AstraZeneca Plc, H1 2018
Hypercholesterolemia - Pipeline by BioLingus AG, H1 2018
Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2018
Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Hypercholesterolemia - Pipeline by CymaBay Therapeutics Inc, H1 2018
Hypercholesterolemia - Pipeline by Daewon Pharm Co Ltd, H1 2018
Hypercholesterolemia - Pipeline by Daewoong Co Ltd, H1 2018
Hypercholesterolemia - Pipeline by Dicerna Pharmaceuticals Inc, H1 2018
Hypercholesterolemia - Pipeline by Dybly AG, H1 2018
Hypercholesterolemia - Pipeline by Esperion Therapeutics Inc, H1 2018
Hypercholesterolemia - Pipeline by Gemphire Therapeutics Inc, H1 2018
Hypercholesterolemia - Pipeline by Golden Biotechnology Corp, H1 2018
Hypercholesterolemia - Pipeline by Immune Response BioPharma Inc, H1 2018
Hypercholesterolemia - Pipeline by Innovent Biologics Inc, H1 2018
Hypercholesterolemia - Pipeline by Kadmon Corp LLC, H1 2018
Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Hypercholesterolemia - Pipeline by Leading BioSciences Inc, H1 2018
Hypercholesterolemia - Pipeline by LipimetiX Development Inc, H1 2018
Hypercholesterolemia - Pipeline by Madrigal Pharmaceuticals Inc, H1 2018
Hypercholesterolemia - Pipeline by Medlab Clinical Ltd, H1 2018
Hypercholesterolemia - Pipeline by Noxopharm Ltd, H1 2018
Hypercholesterolemia - Pipeline by Pfizer Inc, H1 2018
Hypercholesterolemia - Pipeline by Portola Pharmaceuticals Inc, H1 2018
Hypercholesterolemia - Pipeline by Progenra Inc, H1 2018
Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Hypercholesterolemia - Pipeline by RegenxBio Inc, H1 2018
Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
Hypercholesterolemia - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2018
Hypercholesterolemia - Pipeline by The Medicines Company, H1 2018
Hypercholesterolemia - Pipeline by Viking Therapeutics Inc, H1 2018
Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2018
Hypercholesterolemia - Dormant Projects, H1 2018
Hypercholesterolemia - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Hypercholesterolemia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report